Figure 2From: Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?Comparisons of sclerostin serum levels in ankylosing spondylitis (AS) patients at baseline, 6 months and 12 months after anti-TNF therapy and in healthy controls.Back to article page